N/A
N=933
Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Open-Angle Glaucoma · Ocular Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT01568008 ↗Enrolled (actual)
933
Serious AEs
0.8%
Results posted
Sep 2013
Primary outcome: Primary: Intraocular Pressure (IOP) at Baseline — 22.04; 22.07 mm Hg
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Bimatoprost 0.01% ophthalmic solution (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Sep 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intraocular Pressure (IOP) at Baseline |
22.04; 22.07 | — |
| PRIMARY Intraocular Pressure (IOP) at Week 12 |
16.94; 17.02 | — |
| SECONDARY Patient Assessment of Treatment Tolerability Using a 4-Point Scale |
460; 317; 61; 50 | — |
| SECONDARY Physician Assessment of Treatment Tolerability Using a 4-Point Scale |
489; 331; 49; 24 | — |
| SECONDARY Physician Reported Reasons for Treatment Discontinuation |
46; 20; 11; 8; 6; 6 | — |
| SECONDARY Number of Patients Continuing Treatment After 12 Weeks |
755 | — |
Summary
This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting. Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after baseline, as per normal clinical practice.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of POAG or OHT
- Prescribed Lumigan® 0.01%
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01568008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.